Form 4 for DGX Quest Diagnostics
Accepted 2026-04-24 18:23:04 ET · period of report 2026-04-20 · accession 0001022079-26-000044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 18:23 | 2026-04-20 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | L - Small Acq | $194.70 | +37 | 11.9K | +0.3% | +$7,204 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-20 | L | A | 37 | $194.70 | 11,901 | D | — | — | (F1) Represents an award of restricted share units. (F2) Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4. |